Cambridge Antibody Technology (CAT) and Scil Proteins GmbH have signed a cross-licence agreement, the two companies have announced.

Under the agreement, both parties will have the freedom to conduct research under certain of each others' intellectual property, as well as the right to develop a number of therapeutic, diagnostic and technical products.

CAT have also been given access to Scil Proteins' Affilin™ technology, while Scil Proteins will have the rights to intellectual property in Ribosome Display controlled by CAT in the field of novel protein products.

In addition, Scil Proteins receives the right to sublicense the products to third parties.

CAT has also obtained not only the right to develop and commercialise therapeutic Affilin based products using Scil Proteins' proprietary scaffold technology, including the right to sublicense to collaboration partners, but can also use Scil Proteins' protein refolding know-how to enforce CAT's product developments.

CAT's senior vice president of discovery Dr Alex Duncan said: “We view this cross-licence agreement with Scil Proteins as important to our continuing commitment to increasing the range of technologies that CAT can apply to the development and commercialisation of therapeutic proteins.

“By working with companies such as Scil Proteins we aim to strengthen our leadership position in this field.”

© Crimson Business Ltd. 2006